AmberGen receives US Patent 10,088,474 for its pioneering PC-PURE technology for multiplex Allergy diagnostics.
Archives: Company News
Company news stories
AmberGen receives US Patent 10,060,912 for global proteomic screening of random bead-arrays using mass spectrometric imaging
AmberGen receives US Patent 10,060,912 for global proteomic screening of random bead-arrays using mass spectrometric imaging.
AmberGen receives US Patent 9,910,034 for its innovative PC-PURE technology for photo-affinity biomarker enrichment
AmberGen receives US Patent 9,910,034 for its innovative PC-PURE technology for photo-affinity biomarker enrichment.